Qiagen N.V. QGEN
Composite 61/100; the shares have moved about 37% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Income ranks 42/100 — a slight mark against it.
Balance-sheet strength ranks 79/100 — a strong point in its favour. Growth ranks 72/100 — a moderate point in its favour. Quality ranks 63/100 — a moderate point in its favour.
Income ranks 42/100 — a slight mark against it. Valuation ranks 47/100 — a slight mark against it. Momentum ranks 48/100 — a slight mark against it.
What the company does Qiagen N.V. (QGEN) provides sample-to-insight solutions, transforming biological samples into molecular insights via consumables and instruments for nucleic acid analysis, diagnostics, and research applications.
Key financials Revenue grew 2% while EPS fell 24% YoY. Margins remain robust: gross 66%, operating 24%, net 19%. ROE 12%, ROA 6%, ROCE 9%. Debt/equity 0.50, interest coverage 13x, current ratio 3.21.
Stock health Quality score 62/100; growth 31/100, momentum 40/100. Piotroski F-Score 7/9, Altman Z 3.62. RSI(14) 58, 1-day -0.24%.
Price vs fair value The stock trades at a discount to both our fair-value estimate and analyst targets: - Price is trading at a discount of 3.20% versus our fair-value estimate of 42.69. - Price is trading at a discount of 6.58% versus the 12-month target of 44.07 (analyst count 14). - Recent headlines highlight earnings headwinds: "Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings" (Zacks 2026-07-29) and sector rotation toward peers like Cytokinetics (Zacks 2026-07-30).
Looking forward Forward P/E 13x (vs trailing 21x) and PEG 0.21 suggest potential valuation appeal if growth stabilizes. Consensus hinges on execution in diagnostics and oncology amid competitive pressure.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.